Get the Stockscreener App
592.37
2.12%
12.48
Madrigal Pharmaceuticals Inc stock is traded at $592.37, with a volume of 104.21K.
It is up +2.12% in the last 24 hours and up +33.18% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$579.89
Open:
$582.59
24h Volume:
104.21K
Relative Volume:
0.30
Market Cap:
$13.45B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-23.58
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-1.47%
1M Performance:
+33.18%
6M Performance:
+112.00%
1Y Performance:
+85.94%
1-Day Range:
$573.00
$593.69
1-Week Range:
$569.04
$605.00
52-Week Range:
$265.00
$605.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
592.32 | 13.17B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.83 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.01 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.45 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
920.22 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.18 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - MarketScreener
Lobbying Update: $30,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PR Newswire
Can Madrigal Pharmaceuticals Inc. (YDO1) stock double in coming yearsWall Street Watch & Stock Portfolio Risk Control - Newser
How Madrigal Pharmaceuticals Inc. (YDO1) stock valuation compares with sectorWeekly Trade Review & Real-Time Buy Signal Notifications - Newser
Why analysts remain bullish on Madrigal Pharmaceuticals Inc. stockQuarterly Trade Review & Risk Controlled Daily Plans - Newser
Why Madrigal Pharmaceuticals Inc. (YDO1) stock signals breakout potentialChart Signals & AI Enhanced Market Trend Forecasts - Newser
Published on: 2025-12-04 02:06:23 - Newser
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockWeekly Investment Recap & Fast Gain Stock Trading Tips - Newser
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth story2025 Technical Patterns & Free Community Consensus Stock Picks - Newser
Madrigal Pharma EVP Dier sells $2.4m in MDGL stock By Investing.com - Investing.com South Africa
Madrigal Pharma EVP Dier sells $2.4m in MDGL stock - Investing.com
MDGL: Billion-dollar run rate, expanding prescriber base, and robust pipeline drive long-term growth - TradingView
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikesJuly 2025 Pullbacks & High Accuracy Investment Signals - Newser
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug - Insider Monkey
Madrigal Pharmaceuticals Inc (YDO1.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Why (MDGL) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - MSN
Is Madrigal Pharmaceuticals Still Attractively Priced After 42.6% Surge on R&D Progress? - Yahoo Finance
Why retail traders accumulate Madrigal Pharmaceuticals Inc. (YDO1) stock2025 Support & Resistance & Precise Swing Trade Alerts - moha.gov.vn
Madrigal Grants New Equity Awards as Hiring Builds Momentum Around MASH Drug - MSN
Is Madrigal Pharmaceuticals Inc. stock vulnerable to regulatory risks2025 Valuation Update & Weekly Sector Rotation Insights - BỘ NỘI VỤ
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MSN
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockCandlestick Pattern Analysis & Small Capital Gains - earlytimes.in
Biopharma Giant Draws Spotlight With High-Stakes Investor Talks on MASH Breakthrough - MyChesCo
Madrigal Pharmaceuticals stock hits all-time high of 578.8 USD By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals stock hits all-time high of 578.8 USD - Investing.com
Madrigal Pharma: Inside the MAESTRO-NASH Breakthrough- How Weight Loss Supercharges Antifibrotic Effects! - Smartkarma
A Look at Madrigal Pharmaceuticals’s Valuation Following Positive Phase 3 Rezdiffra Results for MASH Cirrhosis - Sahm
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 - MSN
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,082,986, According to a Recent SEC Filing - MarketScreener
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Madrigal Pharmaceuticals stock price target raised to $620 by H.C. Wainwright - Investing.com Canada
Madrigal Pharmaceuticals (MDGL) Sees Analyst Upgrade with Target - GuruFocus
Can Madrigal Pharmaceuticals Inc. stock sustain market leadership2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Jefferies 25: The Cardiometabolic Revolution Is Going Global - Citeline News & Insights
Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating - MarketScreener
What margin trends mean for Madrigal Pharmaceuticals Inc. stockChart Signals & Momentum Based Trading Ideas - newser.com
Madrigal Pharmaceuticals (MDGL): Oppenheimer Raises Price Target - GuruFocus
Oppenheimer raises Madrigal Pharmaceuticals stock price target on positive Rezdiffra data - Investing.com Canada
Will Madrigal Pharmaceuticals Inc. stock pay special dividendsJuly 2025 PostEarnings & Pattern Based Trade Signal System - newser.com
Is Madrigal Pharmaceuticals Inc. (YDO1) stock in buy zone after pullbackPortfolio Return Report & Low Volatility Stock Suggestions - newser.com
How Madrigal Pharmaceuticals Inc. (YDO1) stock reacts to Fed tighteningJuly 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
Why Madrigal Pharmaceuticals Inc. (YDO1) stock is listed among top recommendationsTrade Ideas & Real-Time Price Movement Reports - newser.com
Madrigal Pharmaceuticals stock price target raised by Truist on MASH potential - Investing.com South Africa
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Madrigal Pharmaceuticals Inc Stock (MDGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dier Mardi | EVP and CFO |
Dec 02 '25 |
Sale |
578.34 |
4,173 |
2,413,416 |
10,440 |
1.09%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):